[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647582":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":35,"centralContacts":39,"locations":22,"responsibleParty":44,"collaborators":22,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":22,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":22,"enrollmentInfo":55,"targetDuration":22,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":68,"overallStatus":72,"whyStopped":22,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":22},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Digital Cognitive Assessment","Participants with newly diagnosed PCNSL or IDH-mutant LGG will undergo both traditional neuropsychological testing and digital cognitive assessments (TestMyBrain and Mobile Toolbox) at specified timepoints (baseline, 6 months, post-treatment or 12-14 months). Quality of life and mood questionnaires will also be administered. Brain MRI data will be collected as part of standard care. Participants will be sent a link to complete the digital cognitive tests at home. Questionnaires will also be sent via email to complete. Data will be collected from brain MRIs obtained as part of standard of care\u002Froutine surveillance.\n\n* Screening visit\n* Baseline visit (2- months)\n* Follow-Up visit (3-month)\n* End of Treatment 2 months after completing treatment (PCNSL only)\n* Final Assessment 12-14 months after baseline (LGG only).\n* Brain MRI (standard of care) based on participant permission\n\nThere is no follow-up care as part of this research study.",[12,13,14,15],"Behavioral: Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox)","Behavioral: Traditional Neuropsychological Testing","Other: Quality of Life and Mood Questionnaires","Other: Brain MRI (Standard of Care)",[17,23,27,31],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"BEHAVIORAL","Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox)","Participants will complete a battery of digital cognitive tests using the TestMyBrain and Mobile Toolbox platforms, assessing attention, processing speed, executive function, and memory. Assessments will be conducted in clinic and at home at multiple timepoints.",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Traditional Neuropsychological Testing","Participants will complete standard paper-and-pencil neuropsychological tests, including WAIS-IV Digit Span, Brief Test of Attention, Symbol Digits Modalities Test, Trail Making Test Parts A and B, Stroop, and Hopkins Verbal Learning Test-Revised.",[9],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"Quality of Life and Mood Questionnaires","Participants will complete the Functional Assessment of Cancer Therapy - Brain (FACT-br) and Hospital Anxiety and Depression Scale (HADS) at baseline and follow-up timepoints.",[9],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":22},"Brain MRI (Standard of Care)","Brain MRI data will be collected as part of routine clinical care to assess tumor response, stability, or progression, and correlated with cognitive test results.",[9],[36],{"name":37,"affiliation":5,"role":38},"Lakshmi Nayak, MD","PRINCIPAL_INVESTIGATOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":22,"email":43},"CONTACT","617-632-2166","Lakshmi_Nayak@dfci.harvard.edu",{"type":38,"investigatorFullName":37,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Principal Investigator","100647582","neurocognitive-assessment-cnsl-and-lgg-100647582",false,"NCT07710131","Neurocognitive Assessment CNSL and LGG","Neurocognitive Evaluation Using Digital Technology: A Pilot Study in Primary Central Nervous System Lymphoma and Low-grade Gliomas","Inclusion Criteria:\n\n* Histopathologically confirmed newly diagnosed primary CNS diffuse large B-cell lymphoma (DLBCL) OR\n* Histopathologically confirmed IDH-M low grade glioma diagnosis in the past 12 months who have not started tumor directed therapy (if applicable).\n* Age ≥ 18 years.\n* Ability to consent to study.\n\nExclusion Criteria:\n\n* Patients who have severe visual impairment that cannot be corrected with glasses to read regular sized print.\n* Patients who have known psychiatric or substance abuse disorders that would interfere with their cooperation in completing the requirements of the study.","ALL","18 Years",{"count":56,"type":57},36,"ESTIMATED","INTERVENTIONAL",[60],"NA","This study is to determine whether self-administered digital cognitive tests can serve as accurate and reliable alternatives to established neuropsychological tests for evaluating cognitive functioning in participants with primary central nervous system lymphoma and low-grade gliomas.",[63,64,65,66,67],"PCNSL","Brain Tumor","Cognitive Dysfunction","IDH Mutation","Low-grade Glioma",[69,70,71,65],"Primary Central Nervous System Lymphoma (PCNSL)","IDH-Mutant Low-Grade Glioma (LGG)","Brain Tumors","NOT_YET_RECRUITING","2026-07-13",{"date":75,"type":76},"2026-07-17","ACTUAL",{"date":78,"type":57},"2026-09-01",{"date":80,"type":57},"2029-01-01",{"name":5,"class":6}]